Details

Autor(en) / Beteiligte

• Haycroft, Ebene R
• Damelang, Timon
• Lopez, Ester
• Rodgers, Mark A
• Wines, Bruce D
• Hogarth, Mark
• Ameel, Cassaundra L
• Kent, Stephen J
• Scanga, Charles A
• O'Connor, Shelby L
• Chung, Amy W

Titel

Antibody glycosylation correlates with disease progression in SIV- Mycobacterium tuberculosis coinfected cynomolgus macaques

Ist Teil von

• Clinical & translational immunology, 2023, Vol.12 (11), p.e1474-e1474

Ort / Verlag

Australia: John Wiley & Sons, Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Wiley Online Library Journals【キャンパス外アクセス可】

Beschreibungen/Notizen

• Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV-positive individuals remain largely unknown. Here, we used a simian immunodeficiency virus (SIV)/TB-coinfection Mauritian cynomolgus macaque (MCM) model to examine humoral responses from the plasma of SIV-negative (  = 8) and SIV-positive (  = 7) MCM 8-week postinfection with ( ). Antibody responses to were impaired during SIV coinfection. Elevated inflammatory bulk IgG antibody glycosylation patterns were observed in coinfected macaques early at 8-week post- infection, including increased agalactosylation (G0) and reduced di-galactosylation (G2), which correlated with endpoint bacterial burden and gross pathology scores, as well as the time-to-necropsy. These studies suggest that humoral immunity may contribute to control of TB disease and support growing literature that highlights antibody Fc glycosylation as a biomarker of TB disease progression.